Expert Strategies for Identifying Eligible Patients With DLBCL and FL for CAR T-Cell Therapy

Upon completion of this activity, participants should be better able to assess current practice patterns to identify facilitators and barriers to the timely referral of patients eligible for chimeric antigen receptor (CAR) T-cell therapy for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)

Upon completion of this activity, participants should be better able to identify patients eligible for CAR T-cell therapy based on NHL subtype, line of therapy, and patient-specific factors to facilitate optimal referral timing and processes

Upon completion of this activity, participants should be better able to employ interprofessional team-based strategies to improve referral, treatment, communication, and care coordination between oncology clinics and CAR T-cell centers to optimize outcomes for patients with DLBCL/FL